Medical products have dramatically revolutionized how diseases are treated or prevented. At the same time, inappropriate use of these products is associated with increased incidence of adverse reactions. This problem is acute in resource-limited countries in the absence of adequate monitoring systems. This book examines and highlights the critical role and need for pharmacovigilance systems in these settings. Issues unique to these countries are explored, including medical product safety and quality problems; the nature of support needed to build pharmacovigilance system capacity to effective levels; global and regional strategies and efforts to develop institutional and professional capacity; the challenges being faced and how these are being tackled. This book is a must-read resource for anyone involved in the provision of safe, and quality medical products; and its rational use. "This book is unique in its focus on pharmacovigilance in resource-limited countries." Hubert G Leufkens, PhD, FISPE, Professor of Pharmaceutical Policy and Regulatory Science, Utrecht Institute for Pharmaceutical Sciences (UIPS), Former Head of the Dutch regulatory agency (MEB), The Netherlands "I foresee this collection will become a very useful reference for everyone working or supporting the development of pharmacovigilance in countries with limited resources." Adel Al-Harf, Ph.D., Vice President of the Drug Sector, Saudi Food and Drug Authority (SFDA), Kingdom of Saudi Arabia Dr. Ahmad is a drug safety consultant who served the U.S. FDA for 15 years. He received his medical degree from Dow Medical College, Karachi; public health degree from Johns Hopkins, Baltimore, and did clinical pharmacology fellowship at Georgetown University, Washington, DC. Dr. Ahmad has a passion to train regulators and help establish pharmacovigilance centres. He has conducted pharmacovigilance training in Eswatini, Cambodia, Kuwait, Laos, Oman, the Philippines, Pakistan, Palestine, Saudi Arabia, and the UAE. Dr. Ahmad has contributed chapters on pharmacovigilance, and the FDA approval process in seven texts including the past editions of Brian Strom's 'Textbook of Pharmacoepidemiology' and Ronald Mann's 'Pharmacovigilance'.